{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:03:28Z","timestamp":1785899008521,"version":"3.56.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1093\/ndt\/gfl198","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T00:19:17Z","timestamp":1146183557000},"page":"2133-2143","source":"Crossref","is-referenced-by-count":116,"title":["Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease"],"prefix":"10.1093","volume":"21","author":[{"given":"Chris","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Rogerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"key\n\t\t\t\t20171012185326_BIB1","doi-asserted-by":"crossref","unstructured":"Coresh J, Astor BC, Greene T, et al. Prevalence of Chronic Kidney Disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kid Dis2003; 41: 1\u201312","DOI":"10.1053\/ajkd.2003.50007"},{"key":"key\n\t\t\t\t20171012185326_BIB2","doi-asserted-by":"crossref","unstructured":"John R, et al. Unreferred chronic kidney disease: a longitudinal study. Am J Kid Dis2004; 43: 825\u2013835","DOI":"10.1053\/j.ajkd.2003.12.046"},{"key":"key\n\t\t\t\t20171012185326_BIB3","doi-asserted-by":"crossref","unstructured":"De Vecchi AF, Dratwa M, Wiedermann ME. Healthcare systems and ESRD therapies \u2013 an international review. Costs and reimbursement\/funding of ESRD therapies. Nephrol Dial Transplant1999; 14 [Suppl 6]: 31\u201341","DOI":"10.1093\/ndt\/14.suppl_6.31"},{"key":"key\n\t\t\t\t20171012185326_BIB4","unstructured":"United States Renal Data System (USRDS). USRDS Annual Report (2003): incidence and prevalence of ESRD. Am J Kid Dis2003; 42 [Suppl 5]"},{"key":"key\n\t\t\t\t20171012185326_BIB5","doi-asserted-by":"crossref","unstructured":"Roderick P, Davies R, Jones C, et al. Simulation model of renal replacement therapy: predicting future demand in England. Nephrol Dial Transplant2004; 19: 692\u2013701","DOI":"10.1093\/ndt\/gfg591"},{"key":"key\n\t\t\t\t20171012185326_BIB6","doi-asserted-by":"crossref","unstructured":"Wight JP, Oliver A, Payne N. A computer model for predicting the demand for end-stage renal failure (ESRF) treatment, contract setting and monitoring. Nephrol Dial Transplant1996; 11: 1286\u20131291","DOI":"10.1093\/ndt\/11.7.1286"},{"key":"key\n\t\t\t\t20171012185326_BIB7","doi-asserted-by":"crossref","unstructured":"Briggs JD, Berthoux F, Jones E. Predictions for future growth of ESRD prevalence. Kidney Int2000; 57: 46\u201348","DOI":"10.1046\/j.1523-1755.2000.07408.x"},{"key":"key\n\t\t\t\t20171012185326_BIB8","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Lokkegaard H. Predicting future trends in the number of patients on renal replacement therapy in Denmark. Nephrol Dial Transplant1997; 12: 2117\u20132123","DOI":"10.1093\/ndt\/12.10.2117"},{"key":"key\n\t\t\t\t20171012185326_BIB9","doi-asserted-by":"crossref","unstructured":"Xue JL, Jennie Z, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol2001; 12: 2753\u20132758","DOI":"10.1681\/ASN.V12122753"},{"key":"key\n\t\t\t\t20171012185326_BIB10","doi-asserted-by":"crossref","unstructured":"Branley P, McNeil JJ, Stephenson DH, et al. Modelling the future dialysis requirements under various scenarios of organ availability in Australia. Nephrology2000; 5: 243\u2013249","DOI":"10.1046\/j.1440-1797.2000.00010.x"},{"key":"key\n\t\t\t\t20171012185326_BIB11","unstructured":"Department of Health. The National Service Framework for Renal Services Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life care. 2005. London, Department of Health"},{"key":"key\n\t\t\t\t20171012185326_BIB12","unstructured":"Anonymous: K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kid Dis2002; 39 [Suppl 2]: S7\u2013S246"},{"key":"key\n\t\t\t\t20171012185326_BIB13","doi-asserted-by":"crossref","unstructured":"Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int1997; 51: 1908\u20131919","DOI":"10.1038\/ki.1997.260"},{"key":"key\n\t\t\t\t20171012185326_BIB14","doi-asserted-by":"crossref","unstructured":"Vanholder RC, Massy ZA, Argiles A, Spasovski G, Verbeke F, Lamiere N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant2005; 20: 1048\u20131056","DOI":"10.1093\/ndt\/gfh813"},{"key":"key\n\t\t\t\t20171012185326_BIB15","doi-asserted-by":"crossref","unstructured":"Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organisation. Arch Intern Med2004; 164: 659\u2013663","DOI":"10.1001\/archinte.164.6.659"},{"key":"key\n\t\t\t\t20171012185326_BIB16","doi-asserted-by":"crossref","unstructured":"Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease (the modification of diet in renal disease study). Ann Intern Med1995; 123: 754\u2013762","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"key\n\t\t\t\t20171012185326_BIB17","doi-asserted-by":"crossref","unstructured":"Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and the progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med2001; 135: 73\u201387","DOI":"10.7326\/0003-4819-135-2-200107170-00007"},{"key":"key\n\t\t\t\t20171012185326_BIB18","doi-asserted-by":"crossref","unstructured":"Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kid Dis2000; 35: 695\u2013707","DOI":"10.1016\/S0272-6386(00)70018-7"},{"key":"key\n\t\t\t\t20171012185326_BIB19","doi-asserted-by":"crossref","unstructured":"Feest TG, Dunn EJ, Burton CJ. Can intensive treatment alter the progress of established diabetic nephropathy to end stage renal failure? Q J Med1999; 92: 275\u2013282","DOI":"10.1093\/qjmed\/92.5.275"},{"key":"key\n\t\t\t\t20171012185326_BIB20","doi-asserted-by":"crossref","unstructured":"Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int2004; 66: 1596\u20131605","DOI":"10.1111\/j.1523-1755.2004.00925.x"},{"key":"key\n\t\t\t\t20171012185326_BIB21","doi-asserted-by":"crossref","unstructured":"Jones C, Roderick P, Harris S, Rogerson M. An evaluation of a shared Primary and Secondary Care Nephrology Service for managing patients with moderate to advanced CKD. Am J Kid Dis2006; 47: 103\u2013114","DOI":"10.1053\/j.ajkd.2005.09.020"},{"key":"key\n\t\t\t\t20171012185326_BIB22","unstructured":"The Joint Specialty Committee on Renal Disease of the Royal College of Physicians of London and the Renal Association. Guidelines for Chronic Kidney Disease: Identification, management and referral: Draft documents December 2004. http:\/\/www.renal.org\/JSCRenalDisease\/JSCRenalDisease.html. 2005"},{"key":"key\n\t\t\t\t20171012185326_BIB23","unstructured":"Renal Association. Treatment of adults and children with renal failure. Standards and audit measures 3rd edn, London: The Royal College of Physicians, 2002"},{"key":"key\n\t\t\t\t20171012185326_BIB24","doi-asserted-by":"crossref","unstructured":"Levey AS, Bosch JP, Breyer Lewis J, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med1999; 130: 461\u2013470","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"key\n\t\t\t\t20171012185326_BIB25","unstructured":"Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol2000; 11: 155A"},{"key":"key\n\t\t\t\t20171012185326_BIB26","unstructured":"National Kidney Foundation. NKF K\/DOQI Guidelines: Definition and classification of stages of chronic kidney disease. http:\/\/www.kidney.org. 2002. 1-5-2005"},{"key":"key\n\t\t\t\t20171012185326_BIB27","doi-asserted-by":"crossref","unstructured":"Levey AS. Nondiabetic kidney disease. N Engl J Med2002; 347: 1505\u20131511","DOI":"10.1056\/NEJMcp013462"},{"key":"key\n\t\t\t\t20171012185326_BIB28","doi-asserted-by":"crossref","unstructured":"Levey AS, Gassman JJ, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. J Am Soc Nephrol1991; 1: 1087\u20131094","DOI":"10.1681\/ASN.V191087"},{"key":"key\n\t\t\t\t20171012185326_BIB29","doi-asserted-by":"crossref","unstructured":"Van Biesen W, Vanholder R, Veys N, et al. The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. Nephrol Dial Transplant2006; 21: 77\u201383","DOI":"10.1093\/ndt\/gfi185"},{"key":"key\n\t\t\t\t20171012185326_BIB30","doi-asserted-by":"crossref","unstructured":"Coresh J, Eknoyan G, Levey AS. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol2002; 13: 2811\u20132812","DOI":"10.1097\/01.ASN.0000037420.89149.C9"},{"key":"key\n\t\t\t\t20171012185326_BIB31","doi-asserted-by":"crossref","unstructured":"Froissart M, Rossert J, Jacqout C, Paillard M, Houillier P. Predictive performance of the Modification of Diet in Renal Disease and Cockroft\u2013Gault equations for estimating renal function. J Am Soc Nephrol2005; 16: 763\u2013773","DOI":"10.1681\/ASN.2004070549"},{"key":"key\n\t\t\t\t20171012185326_BIB32","doi-asserted-by":"crossref","unstructured":"Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special epmhasis on calibration of the serum creatinine assay. Am J Kid Dis2004; 44: 84\u201393","DOI":"10.1053\/j.ajkd.2004.03.027"},{"key":"key\n\t\t\t\t20171012185326_BIB33","doi-asserted-by":"crossref","unstructured":"Lamb EJ, Tomson CRV, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem2005; 42: 321\u2013345","DOI":"10.1258\/0004563054889936"},{"key":"key\n\t\t\t\t20171012185326_BIB34","doi-asserted-by":"crossref","unstructured":"Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol2002; 13: 2140\u20132144","DOI":"10.1097\/01.ASN.0000022011.35035.F3"},{"key":"key\n\t\t\t\t20171012185326_BIB35","unstructured":"Department of Health. National service framework for coronary heart disease: modern standards and service models. London: Department of Health, 2000"},{"key":"key\n\t\t\t\t20171012185326_BIB36","unstructured":"Department of Health. National service framework for diabetes standards. London: Department of Health, 2001"},{"key":"key\n\t\t\t\t20171012185326_BIB37","doi-asserted-by":"crossref","unstructured":"Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA2002; 287: 2570\u20132581","DOI":"10.1001\/jama.287.19.2570"},{"key":"key\n\t\t\t\t20171012185326_BIB38","doi-asserted-by":"crossref","unstructured":"Perneger TV, Brancati FL, Whelton PK, Klag MJ. End stage renal disease attributable to diabetes mellitus. Ann Intern Med1994; 121: 912\u2013918","DOI":"10.7326\/0003-4819-121-12-199412150-00002"},{"key":"key\n\t\t\t\t20171012185326_BIB39","unstructured":"He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens2003; 1999: S7\u2013S13"},{"key":"key\n\t\t\t\t20171012185326_BIB40","doi-asserted-by":"crossref","unstructured":"Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Maschio G. The role of systemic hypertension in the progression of non-diabetic renal disease. Kidney Int2000; 57 [Suppl 75]: S44\u2013S48","DOI":"10.1046\/j.1523-1755.2000.07508.x"},{"key":"key\n\t\t\t\t20171012185326_BIB41","doi-asserted-by":"crossref","unstructured":"Iseki K, Ikemiya Y, Iseki C, et al. Proteinuria and the risk of developing end-stage renal disease. Kidney Int2003; 63: 1468\u20131474","DOI":"10.1046\/j.1523-1755.2003.00868.x"},{"key":"key\n\t\t\t\t20171012185326_BIB42","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837\u2013853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"key\n\t\t\t\t20171012185326_BIB43","doi-asserted-by":"crossref","unstructured":"Pohl MA, Blumenthal S, Cordonnier D, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol2005; 16: 3027\u20133037","DOI":"10.1681\/ASN.2004110919"},{"key":"key\n\t\t\t\t20171012185326_BIB44","doi-asserted-by":"crossref","unstructured":"Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med2005; 142: 342\u2013351","DOI":"10.7326\/0003-4819-142-5-200503010-00009"},{"key":"key\n\t\t\t\t20171012185326_BIB45","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \u2018Gruppo Italiano di Studi Epidemiologici in Nefrologia\u2019 (GISEN). Kidney Int1998; 53: 1209\u20131216","DOI":"10.1046\/j.1523-1755.1998.00874.x"},{"key":"key\n\t\t\t\t20171012185326_BIB46","doi-asserted-by":"crossref","unstructured":"Strippoli GFM, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. Br Med J2004; 329: 828","DOI":"10.1136\/bmj.38237.585000.7C"},{"key":"key\n\t\t\t\t20171012185326_BIB47","doi-asserted-by":"crossref","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001; 345: 851\u2013860","DOI":"10.1056\/NEJMoa011303"},{"key":"key\n\t\t\t\t20171012185326_BIB48","doi-asserted-by":"crossref","unstructured":"Viberti GC, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progresion to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA1994; 271: 275\u2013279","DOI":"10.1001\/jama.1994.03510280037029"},{"key":"key\n\t\t\t\t20171012185326_BIB49","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999; 354: 359\u2013364","DOI":"10.1016\/S0140-6736(98)10363-X"},{"key":"key\n\t\t\t\t20171012185326_BIB50","doi-asserted-by":"crossref","unstructured":"Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme-inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med1996; 334: 939\u2013945","DOI":"10.1056\/NEJM199604113341502"},{"key":"key\n\t\t\t\t20171012185326_BIB51","unstructured":"Bergstrom J, Alvestrand A, Bucht H, et al. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol1986; 25: 1\u20132"},{"key":"key\n\t\t\t\t20171012185326_BIB52","doi-asserted-by":"crossref","unstructured":"Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med1994; 330: 877\u2013884","DOI":"10.1056\/NEJM199403313301301"},{"key":"key\n\t\t\t\t20171012185326_BIB53","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group: tight blood pressure control and risk of microvascular and macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J1998; 317: 703\u2013713","DOI":"10.1136\/bmj.317.7160.703"},{"key":"key\n\t\t\t\t20171012185326_BIB54","doi-asserted-by":"crossref","unstructured":"Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kid Dis2000; 36: 646\u2013661","DOI":"10.1053\/ajkd.2000.16225"},{"key":"key\n\t\t\t\t20171012185326_BIB55","doi-asserted-by":"crossref","unstructured":"Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation. N Engl J Med2004; 351: 1296\u20131305","DOI":"10.1056\/NEJMoa041031"},{"key":"key\n\t\t\t\t20171012185326_BIB56","doi-asserted-by":"crossref","unstructured":"Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: a pooled analysis of community based studies. J Am Soc Nephrol2004; 15: 1307\u20131315","DOI":"10.1097\/01.ASN.0000123691.46138.E2"},{"key":"key\n\t\t\t\t20171012185326_BIB57","doi-asserted-by":"crossref","unstructured":"Shulman NB, Ford CE, Dallas Hall W, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension1989; 13: I-80\u2013I-93","DOI":"10.1161\/01.HYP.13.5_Suppl.I80"},{"key":"key\n\t\t\t\t20171012185326_BIB58","doi-asserted-by":"crossref","unstructured":"Flack J, Neaton J, Daniels B, et al. Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kid Dis1993; 21: 40","DOI":"10.1016\/S0272-6386(12)80859-6"},{"key":"key\n\t\t\t\t20171012185326_BIB59","doi-asserted-by":"crossref","unstructured":"Wright JT, Bakris G, Greene T, et al. Effect of blod pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA2002; 288: 2421\u20132431","DOI":"10.1001\/jama.288.19.2421"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/8\/2133\/5153603\/gfl198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T05:26:37Z","timestamp":1627277197000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/8\/2133\/1820770\/Decline-in-kidney-function-before-and-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,27]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,4,27]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfl198","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,8]]},"published":{"date-parts":[[2006,4,27]]}}}